LungBlog

Derrel “Buster” Priddy is happy to be a guinea pig for lung cancer research.

“It can only help,” said Priddy, who was diagnosed in August with lung cancer that had spread. “You can’t cure it, but you can beat it.”

New research indicates that lung cancers develop resistance to gefitinib (Iressa) through MET oncogene amplification on ERBB3 signaling.

Our friend U.S. Senator Chuck Hagel has started a groundswell. Since his relentless work on early detection for lung cancer in the Senate with Resolution 408 and 87, the House of Representatives is advancing the heroic efforts with H. Res. 335.

Attorney Bryan Blevins of Provost Umphrey has filed a suit on behalf of refinery worker against A.O. Smith and 42 other corporations for distributing asbestos containing products.The petition says the plaintiff was a lifelong smoker. This is the third case of its type filed by Blevins in the last 30 days.

According to the report, Asian men in New York have greater vulnerability to stomach and lung cancer while men of African origin are at the greatest risk of prostate cancer, and black and Hispanic women have a disproportionately high rate of cervical cancer.

Scientists have discovered a key means by which some lung cancer tumors become resistant to chemotherapy drugs such as Iressa and Tarceva.

Analysis of three genetic mechanisms that cause non-small cell lung cancer might explain why East Asians respond better than other ethnic groups to a certain type of chemotherapy, a team led by UT Southwestern Medical Center researchers has found.

U.S. scientists have developed a method of treating lung cancer tumors that become resistant to anti-cancer drugs.

In the U.S., lung cancer is the biggest cancer killer of all, taking more than 150,000 lives a year.

Research has not slowed the disease much. But now there’s new technology being tested that may save lives in the future.

Drug development is never a smooth process. Last year, Rule Breakers pick Exelixis (Nasdaq: EXEL) experienced a setback with its lead developmental compound, potential cancer treatment XL999. Yesterday, Exelixis announced that the FDA has allowed it to resume testing of the drug and that it was initiating a phase 1 trial in patients with non-small cell lung cancer.